Bioprocessing of cryopreservation for large-scale banking of human pluripotent stem cells.

Department of Chemical and Biomedical Engineering, Florida State University , Tallahassee, Florida.
BioResearch open access 10/2012; 1(5):205-14. DOI: 10.1089/biores.2012.0224
Source: PubMed

ABSTRACT Human pluripotent stem cell (hPSC)-derived cell therapy requires production of therapeutic cells in large quantity, which starts from thawing the cryopreserved cells from a working cell bank or a master cell bank. An optimal cryopreservation and thaw process determines the efficiency of hPSC expansion and plays a significant role in the subsequent lineage-specific differentiation. However, cryopreservation in hPSC bioprocessing has been a challenge due to the unique growth requirements of hPSC, the sensitivity to cryoinjury, and the unscalable cryopreservation procedures commonly used in the laboratory. Tremendous progress has been made to identify the regulatory pathways regulating hPSC responses during cryopreservation and the development of small molecule interventions that effectively improves the efficiency of cryopreservation. The adaption of these methods in current good manufacturing practices (cGMP)-compliant cryopreservation processes not only improves cell survival, but also their therapeutic potency. This review summarizes the advances in these areas and discusses the technical requirements in the development of cGMP-compliant hPSC cryopreservation process.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Stem cells are promising cell sources for many biomedical applications including cell therapy, regenerative medicine, and drug discovery. However, the commonly used static tissue culture vessels can only generate a low number of cells. To provide an adequate number of stem cells for clinical applications, a scalable process based on bioreactors is needed. Stem cells can be either cultured as free cells/aggregates in suspension or as adherent cells on the solid substrates. Based on the cell property, different bioreactor configurations are developed to better expand stem cells while maintaining their differentiation capacity. In this review, several major types of bioreactor systems and their applications in stem cell engineering are discussed. Continued advancements in bioprocess and bioreactor research and development are important to engineer stem cells for their use in biomedical applications.
    Engineering in Life Sciences 01/2014; 14(1). DOI:10.1002/elsc.201300013 · 1.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cell cryopreservation maintains cellular life at sub‐zero temperatures by slowing down biochemical processes. Various cell types are routinely cryopreserved in modern reproductive, regenerative, and transfusion medicine. Current cell cryopreservation methods involve freezing (slow/rapid) or vitrifying cells in the presence of a cryoprotective agent (CPA). Although these methods are clinically utilized, cryo‐injury due to ice crystals, osmotic shock, and CPA toxicity cause loss of cell viability and function. Recent approaches using minimum volume vitrification provide alternatives to the conventional cryopreservation methods. Minimum volume vitrification provides ultra‐high cooling and rewarming rates that enable preserving cells without ice crystal formation. Herein, we review recent advances in cell cryopreservation technology and provide examples of techniques that are utilized in oocyte, stem cell, and red blood cell cryopreservation. Cell cryopreservation is a process commonly used to maintain cellular life at sub‐zero temperatures, but current cell cryopreservation methods can damage cells due to ice crystal formation and toxicity of the cryoprotective agents (CPAs). Vitrification has emerged as an alternative cryopreservation technique to preserve cells without ice crystal formation. In this review, the advantages and challenges associated with the current cell cryopreservation methods are discussed and future directions are highlighted.
    Biotechnology Journal 07/2014; 9(7). DOI:10.1002/biot.201300074 · 3.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Long term cryopreservation of tissue engineering constructs is of paramount importance to meet off-the shelf requirements for medical applications. In the present study, the effect of cryopreservation using natural osmolytes such as trehalose and ectoin with and without conventional Me2SO on the cryopreservation of tissue engineered constructs (TECs) was evaluated. MSCs derived from umbilical cord were seeded on electrospun nanofiberous silk fibroin scaffolds and cultured to develop TECs. TECs were subjected to controlled rate freezing using nine different freezing solutions. Among these, freezing medium consisting of natural osmolytes like trehalose (40mM), ectoin (40mM), catalase (100μg) as antioxidant and Me2SO (2.5%) was found to be the most effective. Optimality of the chosen cryoprotectants was confirmed by cell viability (PI live/dead staining), cell proliferation (MTT assay), microstructure analysis (SEM), membrane integrity (confocal microscopy) and in-vitro osteogenic differentiation (ALP assay, RT-PCR and histology) study carried out with post-thaw cryopreserved TECs. The mechanical integrity of the cryopreserved scaffold was found to be unaltered. The performance of the freezing medium towards cryopreservation of TEC was superior than the performance achieved using conventional Me2SO and similar to the non cryopreserved TEC. Overall we have formulated an efficient freezing medium that may pave the way of long term preservation of TECs with maintaining its integrity, MSCs viability and differentiation potentiality. It was observed that the performance of freezing medium for cryopreservation of TECs was better than the Me2SO.
    Cryobiology 04/2014; DOI:10.1016/j.cryobiol.2014.04.008 · 1.64 Impact Factor

Full-text (2 Sources)

Available from
May 27, 2014